LLY vs NAGE

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Niagen Bioscience Inc (NAGE) shows improved fundamental clarity compared to the previous analysis, with confirmed Q1 2026 profitability (EPS beat, 25% YoY net income growth). Analyst sentiment is strong, with an average price target of $16.33, and a remarkably low PEG ratio of 0.15 signals significant expected growth. The market opportunity in NAD+ supplementation and longevity is substantial, bac...